04 September 2010
Keywords: Canada, Biotechnology industry, Cash availability, Financing, BIOTECanada,
Article | 27 January 2010
Canada’s biotechnology industry is back in gear doing deals at BioPartnering North America and a recent survey finds renewed optimism amongst industry chief executives. The economic situation in 2009 created a new-found flexibility in the sector, as firms restructured and pursued innovative deals and partnering options to survive. Today, companies are in a better situation financially than in December of 2008, and are starting the year on a relatively upbeat note.
“As a CEO actively in the market, I am seeing renewed optimism, and a lot of energy and excitement among investors about the Canadian sector,” said Gordon McCauley, president and CEO of Allon Therapeutics, a Vancouver-based biotechnology company developing treatments for major neurodegenerative conditions. Enjoying this article? To continue reading you need to login, take a FREE trial or subscribe.
FREE unlimited, no obligation access to The Pharma Letter website for 30 days, normally worth £60!
Sign up in less than 60 seconds...no payment needed
Take a no obligations 30 day trial.
Only one trial per user. Find out more details
Subscriptions are £60 per month, pay as you go.
Find out more details.